SuperTrans Medical

Company Overview

Snapshot

Founded in June 2019, SuperTrans Medical operated with 1–10 employees. The company raised $2 million across one funding round from one investor. In September 2021, SuperTrans Medical received support from the U.S. National Institutes of Health (NIH) for developing its lead antibiotic.

Business overview

SuperTrans Medical is a biopharmaceutical company focused on developing novel antibiotics to combat difficult-to-treat, multidrug-resistant bacteria, often referred to as superbugs. The company utilizes its proprietary guanidinium-rich molecular transporter (GR-MoTr) technology, which enhances the antimicrobial properties of existing FDA-approved antibiotics. SuperTrans Medical operates within the Health Tech & Life Sciences sector, specifically targeting the Pharmaceuticals industry with its drug discovery and development efforts.

Strategic signal

In September 2021, SuperTrans Medical secured support from the U.S. National Institutes of Health (NIH) for the development of its lead antibiotic targeting drug-resistant bacteria. This endorsement from a prominent research institution validates the potential of SuperTrans Medical's technology and its approach to addressing urgent public health threats, signaling a strong scientific foundation and potential for accelerated clinical development.

Company Intelligence Q&A

What is SuperTrans Medical's core technology?

SuperTrans Medical develops novel antibiotics using its guanidinium-rich molecular transporter (GR-MoTr) technology, which is designed to enhance the effectiveness of existing FDA-approved antibiotics against multidrug-resistant bacteria.

When was SuperTrans Medical founded?

SuperTrans Medical was founded in June 2019.

What was a significant development for SuperTrans Medical in September 2021?

In September 2021, SuperTrans Medical received support from the U.S. National Institutes of Health (NIH) for the development of its lead antibiotic, which targets urgent threat drug-resistant bacteria.

What was a key strategic partnership for SuperTrans Medical in March 2021?

In March 2021, SuperTrans Medical appointed Australian partners to provide crucial clinical research in the battle against drug-resistant bacteria.

What is the current operational status of SuperTrans Medical?

SuperTrans Medical is currently non-active and ceased to operate in August 2024.